Wellington Management Group LLP Sells 24,227 Shares of Glaukos Co. (NYSE:GKOS)

Wellington Management Group LLP decreased its holdings in Glaukos Co. (NYSE:GKOS) by 1.1% in the 4th quarter, HoldingsChannel reports. The firm owned 2,159,539 shares of the medical instruments supplier’s stock after selling 24,227 shares during the quarter. Wellington Management Group LLP’s holdings in Glaukos were worth $323,801,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. O Shaughnessy Asset Management LLC increased its stake in shares of Glaukos by 4.6% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 4,410 shares of the medical instruments supplier’s stock valued at $661,000 after buying an additional 192 shares in the last quarter. Schroder Investment Management Group increased its position in Glaukos by 213.9% in the 4th quarter. Schroder Investment Management Group now owns 10,259 shares of the medical instruments supplier’s stock valued at $1,538,000 after acquiring an additional 6,991 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Glaukos by 15.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 7,582 shares of the medical instruments supplier’s stock worth $1,137,000 after acquiring an additional 1,041 shares during the last quarter. New Age Alpha Advisors LLC bought a new position in shares of Glaukos in the fourth quarter worth about $451,000. Finally, Norges Bank acquired a new position in shares of Glaukos during the fourth quarter worth approximately $84,490,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on GKOS shares. Truist Financial boosted their price objective on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and upped their price target for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Needham & Company LLC lifted their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Finally, UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $163.25.

Insider Buying and Selling

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Glaukos Trading Down 1.3 %

Shares of NYSE GKOS opened at $97.15 on Wednesday. Glaukos Co. has a twelve month low of $88.16 and a twelve month high of $163.71. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of -33.85 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average is $128.12 and its 200-day moving average is $135.38.

Glaukos (NYSE:GKOS) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Equities research analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.